Q32 Bio to take Homology Medicines’ Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions
The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the biologics maker expects to have about $115 million at the time their deal closes, likely in the first quarter of 2024.
The Massachusetts biotechs follow Lenz Therapeutics and Graphite Bio in joining the reverse merger train, which, by year’s end, is expected to board a few more private companies looking to take the public listing and cash of a biotech that flamed out in the clinic or resorted to “strategic alternatives” for some other reason.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.